The new crown treatment is the recent attention is relatively high popularity track, but many stockholders do not know the new crown treatment concept stock which, today the financial gentleman for the stockholders friends combed out the new crown treatment concept leading stocks list for your reference.
Lian Sheng Chemical (301212)
Zhejiang Lian Sheng Chemical Co., Ltd.'s main business is the research and development, production and sales of ABL, E2, CPMK, GBL, HDO and IPA, as well as the trading business of chemical products. The main products of the company are GBL, ABL, CPMK and E2. the company is one of the top 100 fine chemical companies in 2021, and its main products, such as ABL and E2, have a large scale of production, high product quality, and good business reputation among the companies in the same industry in China.
Rui Zhi Pharmaceuticals (300149)
Rui Zhi Pharmaceuticals Science and Technology Co., Ltd.'s main business consists of two major business segments, respectively, pharmaceutical R & D and production services (CRO/CDMO), micro-ecological nutrition and health care. Pharmaceutical R&D and production services (CRO/CDMO) segment as the company's core business segment, according to the nature of business, pharmaceutical R&D and production services (CRO/CDMO) segment business by the chemical CRO, biological CRO, small molecule CDMO, large molecule CDMO four major service modules. The company's micro-ecological health segment mainly focuses on the production of oligofructose and oligogalactose series of prebiotic products. The company is one of the few leading brands in China that possesses the full-process service capabilities of preclinical CRO (pharmaceutical R&D services) and CMO (pharmaceutical manufacturing services), and is among the top three in the preclinical CRO market.
Price (301257)
Price (Shanghai) Pharmaceutical Technology Development Co., Ltd. provides SMO services to domestic and foreign pharmaceutical companies, medical device companies, and part of the clinical research and development of health-related products. The main service is to provide customers with SMO full-process services to obtain revenue, profit and cash flow. In terms of staff size, the Company is in the first tier of the SMO industry. The Company has more than 2,100 professional business staff, serves more than 600 clinical trial organizations, with a service scope covering more than 140 cities across the country, and possesses a cumulative experience of more than 1,300 international multi-center and domestic clinical projects for new drugs of Class I. The Company's clients include world-renowned foreign companies, medical device companies, and some health-related products. The company's clients include world-renowned foreign pharmaceutical companies and domestic leading new drug R&D companies, providing clinical trial site management for well-known multinational pharmaceutical companies including Pfizer, Roche, Novartis, Johnson & Johnson, AbbVie and Eli Lilly, etc. The SMO services provided by the company are of high quality and efficiency, and are at the advanced level of the same industry in line with the international...
Jiuzhou Pharmaceutical (603456)
Zhejiang Jiuzhou Pharmaceutical (603456) Co., Ltd. is mainly dedicated to providing innovative drug companies and new drug research and development organizations at home and abroad to provide innovative drugs in the research and development, production of CDMO one-stop services; and at the same time for the world's chemical raw materials and pharmaceutical intermediates to provide technology innovation and commercial production business. At the same time, we provide process innovation and commercialization for global chemical APIs and pharmaceutical intermediates. Our products cover central nervous system, non-steroidal anti-inflammatory drugs, hypoglycemic drugs and anti-infective drugs, such as carbamazepine APIs and intermediates, oxcarbazepine APIs and intermediates, pepcidin APIs and intermediates, ketoprofen APIs and intermediates, gliclazide APIs and intermediates, and sulfonamide products. The company has passed the China NMPA (China National Drug Administration), the U.S. FDA (U.S. Food and Drug Administration), the European Union EDQM (European Drug Quality Agency), Japan PMDA (Japan Drug Administration), Italy AIFA (Italy Drug Administration), Mexico CO...
Chengzhi (000990)
Chengzhi (000990) Co., Ltd.'s main business includes the comprehensive operation of industrial gases and basic chemical raw materials, the production of semiconductor display materials, sales of life science and technology products production and sales and industrial hemp cultivation, research, processing and sales of its products. The Company's main products and services include The Company's main products and services include CO, hydrogen and synthesis gas, ethylene, propylene, butanol, octanol and isobutyraldehyde, monochrome liquid crystal materials such as TN and STN, TFT-LCD and OLED materials, D-ribose, L-glutamine, industrial hemp, and the provision of diagnostic, therapeutic and other medical services. As the only company in the world with complete intellectual property rights of D-ribose, the company's subsidiary Chengzhi Bioengineering has passed the audit of the strength can be certified by the company and received AA certificate from BRCGS, which is the second time to receive AA certificate since 2020. The company's subsidiary Chengzhi Yonghua is a high-tech enterprise, a national enterprise technology center, and an optical photonics line in China...
Shenzhou Cell (688520)
Beijing Shenzhou Cell Biotechnology Group Joint Stock Company is an innovative biopharmaceutical research and development company dedicated to the development of biopharmaceuticals with a differentiated competitive advantage, focusing on biopharmaceutical product research and development and industrialization in a number of therapeutic and preventive areas, including malignant tumors, autoimmune diseases, infectious diseases and genetic diseases. The company focuses on R&D and industrialization of biopharmaceutical products in various therapeutic and preventive areas, including malignant tumors, autoimmune diseases, infectious diseases and genetic diseases. Our main products are monoclonal antibodies, vaccines, recombinant proteins and CarT cells. The company has strong capabilities in the discovery and development of innovative drugs, and has independently established a full set of upstream technology platforms for the discovery of innovative biologics, ranging from target protein screening to drug candidates.
Guang Shengtang (300436)
Fujian Guangshengtang (300436) Pharmaceutical Co., Ltd.'s main business is the research and development, production and sales of nucleoside anti-hepatitis B virus drugs; the company's main products are anti-hepatitis B virus drugs, hepatoprotective and liver-protecting drugs, drugs for the digestive system, respiratory drugs, cardiovascular drugs, medical testing services; the company's main products are anti-hepatitis B virus drugs, liver-protecting and liver-protecting drugs, digestive drugs, respiratory drugs, cardiovascular drugs, medical testing services. The company's main products are anti-hepatitis B virus drugs, hepatoprotective drugs, digestive system drugs, respiratory system drugs, cardiovascular drugs, and medical testing services; the company is currently a domestic pharmaceutical enterprise focusing on the field of liver health, and it is the only pharmaceutical enterprise in China that owns four major clinically preferred anti-hepatitis B virus drugs, namely, adefovir, lamivudine, entecavir, and tenofovir, simultaneously.
Huarun Shuanghe (600062)
Huarun Shuanghe (600062) Pharmaceutical Co., Ltd. is the main business for the three major businesses of chronic disease business, specialty business and infusion business. The main products include cotrimoxazole amphotericin tablets (No. 0), cytarabine sodium tablets (Nuobaiyi), amlodipine benzenesulfonate tablets (Presseda), magnesium valproate extended-release tablets (Shentai), gliquinone tablets (Sugar Sipi), soft bags (including straight soft), and inner-seal polypropylene infusion.
Lizhu Group (000513)
Lizhu Pharmaceutical Group Co., Ltd. is mainly engaged in the research and development, production and sales of pharmaceutical products, with the main products covering preparations, APIs and intermediates as well as diagnostic reagents and equipments, and the main products include YiLiAn (Epprazole enteric-coated tablets and Epprazole Sodium for injection), Lizhu The main products include One Lian (Epprazole Enteric Tablets and Epprazole Sodium for Injection), Lizhu Deluxe (Bismuth Potassium Citrate) series products, Beyi (Leuprolide Acetate Microspheres for Injection), Lixinbao (Urinary Follicle Promoter for Injection), Lebold (Urine Prostaglandin for Injection), Ginseng Astragali Fuzhen Injectable Solution, Antiviral Pellet, Lifuokang (Voriconazole for Injection), and Likangle (Murine Nerve Growth Factor for Injection), and other pharmaceuticals and intermediates. The company also produces diagnostic reagents such as HIV antibody diagnostic reagents, Mycoplasma pneumoniae antibody diagnostic reagents and syphilis antibody diagnostic reagents.
Fosun Pharmaceuticals (600196)
Shanghai Fosun Pharmaceuticals (600196) (Group) Company Limited is mainly engaged in the business of pharmaceuticals, medical devices and medical diagnostics, and healthcare services. The main products are core products in the field of treatment of cardiovascular system diseases, core products in the field of treatment of central nervous system diseases, core products in the field of treatment of blood system diseases, core products in the field of treatment of metabolic and digestive system diseases, core products in the field of treatment of anti-infective diseases, core products in the field of treatment of antitumor, core products in the field of APIs and intermediates. According to the 2018 list of the top 100 enterprises in China's pharmaceutical industry issued by the China Pharmaceutical (600056) Industry Information Center of the Ministry of Industry and Information Technology of the People's Republic of China*** and the State of China, the Group was ranked No. 7; according to the IQVIA statistics, in 2019, the Group ranked No. 10 in the country in terms of sales revenue from the hospital-use prescription drugs manufactured by the Group.As one of the largest enterprises in the world in the production, research and development, and manufacture of anti-malarials, the Group has become a member of the Global Fund, United Nations Children's Fund, World Health Organization and drug procurement centers in African countries...